专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005005615A2 ANTI-MULLERIAN INHIBITING SUBSTANCE TYPE II RECEPTOR (MISIIR) IMMUNOCONJUGATES TO DETECT AND TREAT CANCER 审中-公开
标题翻译：抗惊厥药物抑制物质II型受体（MISIIR）免疫调节剂检测和治疗癌症
公开(公告)号：WO2005005615A2
公开(公告)日：2005-01-20
申请号：PCT/US2004/022068
申请日：2004-07-08
申请人： FOX CHASE CANCER CENTER , ADAMS, Gregory, P. , SIMMONS, Heidi, H. , YUAN, Qing-an , MARASCO, Wayne , MEHTA, Smita
发明人： ADAMS, Gregory, P. , SIMMONS, Heidi, H. , YUAN, Qing-an , MARASCO, Wayne , MEHTA, Smita
IPC分类号： C12N
CPC分类号： C07K16/2869 , A61K51/103 , A61K2039/505 , C07K16/2863 , C07K16/3069 , C07K2317/21 , C07K2317/34 , C07K2317/622 , C07K2317/73
摘要： Compositions and methods for detecting and treating cancers expressing Mullerian inhibiting substance Type II receptor (MISIIR) are provided.
摘要翻译：提供了用于检测和治疗表达穆勒抑制物质II型受体（MISIIR）的癌症的组合物和方法。

2. 发明申请

WO2010056893A1 HUMANIZATION AND AFFINITY-OPTIMIZATION OF ANTIBODIES 审中-公开
标题翻译：抗体的人类和亲和力优化
公开(公告)号：WO2010056893A1
公开(公告)日：2010-05-20
申请号：PCT/US2009/064247
申请日：2009-11-12
申请人： IMCLONE LLC , HAIDAR, Jaafar, Nassar Sleiman , YUAN, Qing-an , ZHU, Zhenping
发明人： HAIDAR, Jaafar, Nassar Sleiman , YUAN, Qing-an , ZHU, Zhenping
IPC分类号： C07K16/46 , C12P21/08 , G01N33/48
CPC分类号： C07K16/464 , C07K16/005 , C07K16/2863 , C07K2317/24 , C07K2317/55
摘要： In an efficient selection of higher affinity binders for an antibody humanization strategy, original CDRs are grafted, but no homology modeling is required to determine the key residues in a framework region. One human variable region heavy chain or "VH' and one variable region light chain or 'VL" germline segments show characteristics of high expression in E. coli as a universal template. Key residues in the framework scaffold were determined by screening of available antibody crystal structure data as well as published documents that described the refinements of a specific mouse humanization project. Diversified residues that represent either human antibody selections or mouse selections were integrated into those key framework positions that were assumed to be important in either supporting CDRs or affecting the overall domain structure. A phage display Fab library was used to screen functional reshaped antibodies, which facilitates the isolation of well-maintained clones in a standard panning.
摘要翻译：在用于抗体人源化策略的高亲和力结合物的有效选择中，原始CDR被移植，但是不需要同源建模来确定框架区域中的关键残基。一个人可变区重链或“VH”和一个可变区轻链或“VL”种系显示了在大肠杆菌中作为通用模板的高表达特征。通过筛选可获得的抗体晶体结构数据以及描述特定小鼠人源化项目的改进的公开文献来确定框架支架中的关键残基。代表人抗体选择或小鼠选择的多样化残基被整合到那些被认为在支持CDR或影响整个结构域结构中重要的关键框架位置。使用噬菌体展示Fab文库筛选功能重整抗体，这有助于在标准淘选中分离良好维持的克隆。

3. 发明申请

WO2005005615A3 ANTI-MULLERIAN INHIBITING SUBSTANCE TYPE II RECEPTOR (MISIIR) IMMUNOCONJUGATES TO DETECT AND TREAT CANCER 审中-公开
标题翻译：抗惊厥药物抑制物质II型受体（MISIIR）免疫测定检测和治疗癌症
公开(公告)号：WO2005005615A3
公开(公告)日：2007-06-21
申请号：PCT/US2004022068
申请日：2004-07-08
申请人： FOX CHASE CANCER CT , ADAMS GREGORY P , SIMMONS HEIDI H , YUAN QING-AN , MARASCO WAYNE , MEHTA SMITA
发明人： ADAMS GREGORY P , SIMMONS HEIDI H , YUAN QING-AN , MARASCO WAYNE , MEHTA SMITA
IPC分类号： C07K16/00 , A61K39/00 , C07K14/00 , C07K16/28 , C07K16/30 , C12N20060101 , C12N5/10 , C12N15/00
CPC分类号： C07K16/2869 , A61K51/103 , A61K2039/505 , C07K16/2863 , C07K16/3069 , C07K2317/21 , C07K2317/34 , C07K2317/622 , C07K2317/73
摘要： Compositions and methods for detecting and treating cancers expressing Mullerian inhibiting substance Type II receptor (MISIIR) are provided.
摘要翻译：提供了用于检测和治疗表达穆勒抑制物质II型受体（MISIIR）的癌症的组合物和方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式